Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Multiple lines of evidence support a central role of iron in causing acute kidney injury
(AKI), including the finding that prophylactic administration of iron chelators attenuates
AKI in animal models. Patients undergoing cardiac surgery may be particularly susceptible to
iron-mediated kidney injury due to the profound hemolysis that often occurs from
cardiopulmonary bypass. The investigators will test in a phase 2, randomized, double-blind,
placebo-controlled trial whether prophylactic administration of deferoxamine decreases the
incidence of AKI following cardiac surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborators:
Beth Israel Deaconess Medical Center Massachusetts General Hospital National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)